Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent
Tyra Biosciences, Inc. (TYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients Completed $400 million financing, providing additional capital to advance d
How this was made
The 30-second read
Why it matters
The financing extends cash runway to 2030, while the trial data could de‑risk the upcoming Phase 3 program, likely prompting a short‑term price rally.
Market read
First‑report of material clinical data and a large financing event for a US‑listed biotech, offering a clear trading catalyst.
What to watch
Competitive landscape includes other FGFR inhibitors and potential regulatory delays.
Background
Tyra Biosciences disclosed its Q3 financials, a $400 M capital raise, and initial Phase 2 results for its lead FGFR3‑selective oral candidate dabogratinib.
Ticker impact
Tyra Biosciences filed an 8‑K reporting Q3 2026 results, a $400 M financing, and Phase 2 SURF302 data showing 79% ORR and 64% CR in FGFR3‑altered IR NMIBC.
likely upward pressure as investors price in the strong response rate and extended runway to 2030
First‑report clinical results with high response rates and a sizable financing provide fresh, material catalysts.
Market effects
Boosts sentiment for FGFR‑targeted oncology biotech sector.
Supports US biotech market momentum.
Highlights progress in precision oncology pipelines worldwide.
Counterpoint
Data set is small (n=14) and early‑stage; outcomes may not translate to Phase 3.
Key entities
- companyTyra Biosciences, Inc.
Clinical‑stage biotech developing FGFR‑targeted therapies.
- investorRA Capital Management
Lead underwriter of the $400 M financing.
